In a report released yesterday, Charles Rhyee from TD Cowen maintained a Buy rating on IQVIA Holdings, with a price target of $213.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Charles Rhyee has given his Buy rating due to a combination of factors tied to the strength of IQVIA’s B2B performance and margin outlook. He notes that first-quarter B2B results were distorted by unusually low pass-through activity, and when adjusted for a more typical mix, B2B would have modestly exceeded consensus, indicating solid, margin-accretive underlying demand.
Rhyee also points to IQVIA’s demonstrated operational efficiency, including about 60 basis points of margin expansion, as a foundation for stronger profitability in the second half as foreign-exchange headwinds ease. Management’s view that the depressed pass-through level is a one-off and should normalize in the second quarter reinforces his confidence that the company’s bookings recovery trajectory into 2026 remains intact. The price target is unchanged at $213, reflecting sustained conviction in the stock’s upside potential.
According to TipRanks, Rhyee is a 4-star analyst with an average return of 2.7% and a 48.98% success rate. Rhyee covers the Healthcare sector, focusing on stocks such as IQVIA Holdings, Option Care Health, and Teladoc.